| Home | E-Submission | Sitemap | Contact Us |  
J Korean Soc Ther Radiol Oncol > Volume 28(4); 2010 > Article
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2010;28(4): 219-223. doi: https://doi.org/10.3857/jkstro.2010.28.4.219
In vivo Radiosensitization Effect of HDAC Inhibitor, SK-7041 on RIF-1 Cell Line
Eui Kyu Chie, Jin Hee Shin, In Ah Kim, Il Han Kim
1Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea. ihkim@snu.ac.kr
2Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Korea.
To test the radiosensitizing effect of the newly synthesized novel histone deacetylase inhibitor, SK-7041 in vivo.
The RIF-1 cell line was implanted into the back of a 6-week-old female C3H mouse, intradermally. The mice were grouped into control, drug, radiation (RT), and RT+drug group. SK-7041, 4 mg/kg was administered intraperitoneally for six cycles every 12 hours for mice in the drug and RT+drug group. An identical volume of phosphate buffered saline (PBS) was administered at the same frequency to mice in the control and RT groups. A single 5 Gy fraction was delivered to mice in RT and RT+drug group 6 hours after the fourth delivery. The volume of the implanted tumor was measured every 2~3 days to formulate the growth delay curve.
For the control, drug, RT, and RT+drug groups, the average duration for implanted tumor to reach a volume of 1,500 mm3 was 10 days, 10 days, 9 days, and 12 days, respectively. Moreover, the tumor volume on D14 was 276.7 mm3, 279.9 mm3, 292.5 mm3, and 185.5 mm3, respectively (p=0.0004). The difference for the change in slope for the control and drug versus the RT and RT+drug groups were borderline significant (p=0.0650).
The results of this study indicate that SK-7041 has a radiosensitizing effect for the RIF-I cell line in vivo at a low concentration and this effect may be synergistic. Implementing this result to clinical trial is warranted.
Key Words: Radiation, Histone deacetylase inhibitor, SK-7041, In vivo
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Related article
Editorial Office
Department of Radiation Oncology, Samsung Medical Center,
Proton Therapy Center, B2, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea
Tel : +82-2-3410-3617
E-mail: rojeditor@gmail.com, roj@kosro.or.kr
Copyright © The Korean Society for Radiation Oncology.                      Developed in M2PI
Close layer
prev next